Gilead’s cell therapy business Kite cuts 7% of workforce

Gilead’s cell therapy subsidiary Kite Pharma is letting go of roughly 300 employees, or about 7% of the unit’s staff.

“We are taking measures to further align our business for future growth, including streamlining some areas of the organization to better optimize operational efficiency,” a Gilead spokesperson confirmed in an emailed…
Click here to view original post